<DOC>
	<DOCNO>NCT00121758</DOCNO>
	<brief_summary>This study test safety immune response experimental HIV vaccine , LIPO-5 , healthy volunteer . LIPO-5 contains 5 lipopeptides gag , nef pol correspond 50 epitope . LIPO-5 show immunogenic well tolerate first phase I trial non-HIV infected volunteer . Lower dos peptide could similar immunogenicity .</brief_summary>
	<brief_title>AIDS Vaccine Study Comparing Immunogenicity Safety 3 Doses Lipopeptides Versus Placebo Non Infected HIV Volunteers</brief_title>
	<detailed_description>The aim HIV lipopeptide vaccination approach improve cell mediate immune response order obtain strong , long lasting polyepitopic response focus response highly conserve immunogenic epitope . Lipopeptides chemically synthetized peptide , bear HIV epitope , covalently bound fatty acid moiety , monopalmtoyl chain case . This lipid chain produce internalization lipopeptide cytoplasm antigen present cell . Combinations several lipopeptides contain sequence different HIV protein use vaccination trial order increase polyepitopic response . Lipopeptides synthetized French National Agency Research AIDS Viral Hepatitis ( ANRS ) preventive program group Helen Gras follow long meticulous work epitope screen perform team Jean-GÃ©rard Guillet Cochin Institute Paris . The epitope select basis strong affinity HLA class I molecule , ability form stable complex molecule , capacity epitope recognize T cell . The select peptide contain rich array epitopes frequently recognize HIV infected patient . Each peptide length 23 32 amino acid ( AA ) . Different type lipopeptides construct test human . Among construct , LIPO-5 contain 5 lipopeptides gag , nef pol correspond 50 epitope . LIPO-5 show immunogenic well tolerate first phase I trial non-HIV infected volunteer . Lower dos peptide could similar immunogenicity .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy volunteer select ANRS ( French National Agency Research AIDS Viral Hepatitis ) For woman childbearing age : use effective contraception Ability sign inform consent Beneficiary subject social security regimen Hepatitis B , hepatitis C , HIV , HTLV1 infection syphilis negative Hemoglobin 12.5 g/dl woman 13.5 g/dl men Previous participation HIV clinical trial Volunteers risk contract HIV infection trial Previous vaccination last month , volunteer require vaccination trial Gift blood last 2 month Eczema , urticaria Medical history food allergy , Lyell Stevens Johnson syndrome aggravate asthma Previous ( last 6 month ) ongoing administration immunological treatment , chemotherapy , radiotherapy corticosteroid Medical history autoimmune disease Clinical biological aftermath previous disease Medical history uveitis Transfusion last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>HIV Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>